NASDAQ · Healthcare
Invest in Zhengye Biotechnology stock from India
Indian and foreign residents can buy Zhengye Biotechnology (ZYBT) shares directly through Paasa.
By Paasa · Updated
Zhengye Biotechnology at a glance
- Price
- $1.31-$0.01 (0.38%)
- Market cap
- $61.85M
- Day range
- $1.26 – $1.35
- P/E
- -5.87
- Dividend yield
- None
- Volume
- 19.12K
- 1 month
- -28.69%
- 6 months
- +54.33%
- YTD
- +13.48%
- 1 year
- -29.08%
- 5 years
- -73.15%
Zhengye Biotechnology statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | CN¥116.4M | CN¥186.4M | CN¥211.7M | CN¥260.3M | CN¥214.1M |
| Gross profit | CN¥23.9M | CN¥91.3M | CN¥129.9M | CN¥153.5M | CN¥125.4M |
| Operating income | −CN¥68.3M | CN¥16.4M | CN¥45.0M | CN¥65.8M | CN¥52.4M |
| Net income | −CN¥69.8M | CN¥11.3M | CN¥31.5M | CN¥46.7M | CN¥39.0M |
| Earnings per share | −CN¥1.40 | CN¥0.24 | CN¥0.69 | CN¥1.02 | CN¥0.85 |
| EBITDA | −CN¥42.5M | CN¥42.6M | CN¥72.1M | CN¥85.6M | CN¥70.1M |
| Total assets | CN¥436.5M | CN¥493.2M | CN¥499.9M | CN¥519.7M | CN¥445.3M |
| Total debt | CN¥75.1M | CN¥86.4M | CN¥89.8M | CN¥64.9M | CN¥30.0M |
| Cash and short-term investments | CN¥51.9M | CN¥20.0M | CN¥16.3M | CN¥9.7M | CN¥6.3M |
| Shareholders' equity | CN¥249.8M | CN¥284.0M | CN¥272.9M | CN¥296.5M | CN¥267.5M |
| Operating cash flow | CN¥13.3M | CN¥41.0M | CN¥48.2M | CN¥17.3M | CN¥31.8M |
| Free cash flow | CN¥703.0K | CN¥13.3M | CN¥36.6M | −CN¥10.0M | CN¥5.4M |
| Capital expenditure | −CN¥12.6M | −CN¥27.8M | −CN¥11.6M | −CN¥27.3M | −CN¥26.4M |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in CNY; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Pro-Dex | PDEX | $71.77 | $229.14M |
| Surrozen | SRZN | $29.54 | $220.88M |
| Cardiol Therapeutics | CRDL | $1.71 | $197.12M |
| Apyx Medical | APYX | $2.96 | $124.65M |
| Sera Prognostics | SERA | $2.04 | $77.91M |
| Oncolytics Biotech | ONCY | $0.68 | $68.58M |
| eXoZymes | EXOZ | $6.25 | $57.96M |
| Instil Bio | TIL | $7.17 | $48.63M |
Peers as grouped by the data provider. This is not an investment recommendation.
How to invest in Zhengye Biotechnology from India
Step 1
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Step 2
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit.
Step 3
Search ZYBT and buy
Find Zhengye Biotechnology by name or by its ticker, ZYBT, and place your order. Fractional shares are available and there is no minimum trade size, so you can buy by amount instead of whole shares.
Why invest in Zhengye Biotechnology from India
What Zhengye Biotechnology does
Zhengye Biotechnology Holding Limited specializes in the creation, manufacturing, and commercialization of animal health immunizations. The company primarily supplies the Chinese agricultural sector with vaccines tailored for a broad spectrum of farm animals, including swine, bovines, goats, ovines, and poultry. Zhengye Biotechnology operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
Hold a dollar asset
Zhengye Biotechnology shares are priced in US dollars, so a weaker rupee adds to what they're worth in rupees. The rupee depreciated over 85% against the dollar between 2010 and 2025.
Buy a fraction of a share
Buy by amount, not by share, and get the matching fraction of one Zhengye Biotechnology share. There is no minimum trade size.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
Can I buy Zhengye Biotechnology stock from India?
Yes. Indian residents and NRIs can buy Zhengye Biotechnology (ZYBT) shares directly through Paasa. Zhengye Biotechnology is listed on NASDAQ, in the Drug Manufacturers - Specialty & Generic industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.
Do I need to buy a full Zhengye Biotechnology share?
No. You can buy part of one Zhengye Biotechnology share and add to your position over time. One share is $1.31, and you can buy whole shares or any fraction; there is no minimum trade size.
How are Zhengye Biotechnology dividends taxed for Indian investors?
Zhengye Biotechnology trades on NASDAQ but is domiciled in China, so any withholding on its dividends follows that country's rules rather than those of the US. Some non-US companies list in the US through American Depositary Receipts, which can carry dividend withholding at the company's home-country rate. Dividends are taxed at your slab rate in India. Paasa's dividend report shows the gross amount and any tax withheld for each payment.
What tax do I pay in India when I sell Zhengye Biotechnology shares?
The US does not levy capital gains tax on shares for Indian residents. In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the USD/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.